SCHEMBL5571932

SCHEMBL5571932

Brc1snc2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR3 P46089 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 6/20 0.35
ALDH1A1 P00352 5/20 0.35
HSD17B10 Q99714 3/20 0.35
MAPT P10636 3/20 0.35
HPGD P15428 3/20 0.34
MAOA P21397 2/20 0.34
GLA P06280 2/20 0.34
CASP1 P29466 2/20 0.34
CASP7 P55210 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CHRM2 P08172 1/20 0.34
ADRA2A P08913 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
CHRM1 P11229 1/20 0.34
NQO2 P16083 1/20 0.34
DRD1 P21728 1/20 0.34
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3805823 0.73 GPR3 (0.42) GPR3CYP1A2CYP2C19KDM4EALDH1A1
SCHEMBL15833936 0.73 GPR3 (0.42) GPR3CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL4025561 0.71 KDM4E (0.45) GPR3CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL11877290 0.71 GPR3 (0.40) GPR3CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL11085745 0.71 MAOA (0.44) GPR3CYP1A2CYP2C19KDM4EALDH1A1
SCHEMBL12799106 0.71 GPR3 (0.41) GPR3CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL23495082 0.71 KDM4E (0.38) CYP1A2CYP2C19KDM4EALDH1A1MAPT
SCHEMBL21658663 0.71 AKR1B1 (0.40) GPR3KDM4EALDH1A1HSD17B10MAPT
SCHEMBL15758027 0.71 AKR1B1 (0.43) GPR3CYP1A2CYP2C19KDM4EALDH1A1
SCHEMBL18160956 0.68 ADORA2A (0.39) GPR3CYP1A2CYP2C19KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180044325-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX CLEAVE BIOSCIENCES, INC. 2018-02-15 US disclosed
US-9828363-B2 Fused pyrimidines as inhibitors of P97 complex CLEAVE BIOSCIENCES, INC. (US) 2017-11-28 US disclosed
US-20160355503-A1 NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX CLEAVE BIOSCIENCES, INC. 2016-12-08 US disclosed
US-20160332990-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX CLEAVE BIOSCIENCES, INC. (US) 2016-11-17 US disclosed
EP-1778639-A2 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2007-05-02 EP disclosed
EP-1660427-A4 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2006-12-20 EP disclosed
EP-1660427-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2006-05-31 EP disclosed
WO-2006020049-A2 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2006-02-23 WO disclosed
WO-2005016862-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORPORATION (JP) 2005-02-24 WO disclosed
EP-0751943-A1 TRIAZOLE COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 1997-01-08 EP disclosed
WO-1995025107-A1 TRIAZOLE COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 1995-09-21 WO disclosed
US-4087420-A DYEING AND PRINTING OF HYDROPHOBIC SYNTHETIC FIBERS AND FILMS CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1978-05-02 US disclosed
US-4035143-A HYDROPHOBIC FIBERS AND FILMS, HETEROAROMATIC RADICALS CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332990-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX WDR77, POP1, PSMG3 GPR3 3198/4885CYP1A2 2931/4885CYP2C19 3981/4885
US-20180044325-A1 FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX WDR77, POP1, PSMG3 GPR3 3208/4885CYP1A2 2890/4885CYP2C19 3946/4885
US-20160355503-A1 NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX PSMG3, PSME1, PSME2 GPR3 3337/4885CYP1A2 2609/4885CYP2C19 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.